Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
Atopic dermatitis, also called eczema, is characterized by redness, papulation (skin
elevation) and pruritus (skin itching). The active ingredient of pimecrolimus inhibits the
T-cell activation. These cells are involved in the inflammatory component of the disease.
This study will test the safety of pimecrolimus Cream 1% with topical corticosteroid
treatment (commonly used in eczema) in patients with severe atopic dermatitis.